Therapeutic Class
Syncona launches 3rd gene therapy firm through $120m funding
Therapeutic ClassSyncona launches 3rd gene therapy firm through $120m fundingSyncona launches 3rd gene therapy firm through $120m funding
Ophthalmic gene therapy company Beacon Therapeutics has been launched by Syncona after a £96 million ($120 million) Series A funding round.